Xcout Intel
Numab Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Numab Therapeutics among biotech companies — ranked by similarity to what Numab Therapeutics actually does, not by market-cap band.
Subscribe to see Numab Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Numab Therapeutics
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Numab Therapeutics at a glance
Numab Therapeutics is a biotech company. Xcout tracks 13 named people at Numab Therapeutics, including Barbara Angehrn (Chief Executive Officer).
Numab Therapeutics leadership
- Barbara AngehrnChief Executive Officer
- Stefan WarmuthChief Technology Officer
- Carlo IncertiChairman of the Board
- David UrechDirector, Chair R&D Committee
- Oliver MiddendorpDirector
- Alain BertalloVP People & Culture / IT / Facility Management
7 more named people on record for Numab Therapeutics, with roles, board committees and tenure — see the full roster →
Top 12 Numab Therapeutics competitors
Ranked by semantic similarity — how close each company is to Numab Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Curon Biopharmaceutical is a clinical-stage biotechnology company developing antibody-based medicines, including bispecific antibodies, for cancer and other serious diseases. It serves patients and healthcare providers through the development of therapeutic biologics, with programs intended for oncology and immunology applications.
Biotechnology
Normunity Holding Company, LLC is a biotechnology company developing novel anti-cancer therapies and biologic medicines, including therapeutic antibodies, bispecific antibodies, and T cell engagers. The company utilizes proprietary discovery platforms originating from a partnership with the Yale School of Medicine to target mechanisms at the interface of tumors and the immune system.
Biotechnology
Alchemab Therapeutics Ltd is a biotechnology company headquartered in London, England, focused on pioneering patient-centric antibody discovery and development.
Biotechnology
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
Similar biotech company
Windward Bio is a clinical-stage biotechnology and drug development company headquartered in Basel, Switzerland. It is committed to improving outcomes for people living with serious immunological diseases through its deep discovery, development, and commercialization expertise.
Life Sciences
Northern Biologics is a biotechnology company developing antibody-based therapeutics, with a focus on treating cancer and targeting the tumor microenvironment. Its products are intended for oncology patients and clinical partners in the biopharmaceutical sector.
Biotechnology
Polyneuron Pharmaceuticals is a venture-backed biotech and life sciences company headquartered in Basel, Switzerland. Founded in 2014, the company is pioneering a novel therapeutic approach for the effective and safe treatment of antibody-mediated autoimmune diseases.
Biotechnology
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Similar biotech company
Nimbus Therapeutics is a biotechnology company that uses structure-based drug discovery and computational chemistry to develop small-molecule medicines. It focuses on therapeutic areas including oncology, autoimmune disease, and metabolic disorders, serving patients through internally developed programs and pharmaceutical partnerships.
Biotechnology
Anaveon is a late-stage preclinical biotechnology company based in Basel, Switzerland, focused on developing engineered antibodies for immunotherapy.
Similar biotech company
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Biotechnology
Merus N.V. is a clinical-stage oncology company that discovers and develops antibody treatments for cancer using its proprietary Multiclonics platform. The company serves patients with cancer by advancing innovative therapeutic pipelines. Merus operates as part of Genmab.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Numab Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Numab Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →